(Q35185761)

7 August 2017

1 reference

title

Recent developments in the pharmacological treatment of Parkinson's disease (English)

1 reference

7 August 2017

1 reference

Paul Tuite

1

1 reference

7 August 2017

Jennifer Riss

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Investigational Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

12

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1335-1352

1 reference

Agonists vs levodopa in PD: the thrilla of whitha

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Initial agonist treatment of Parkinson disease: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Slowing Parkinson's disease progression: recent dopamine agonist trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Cloning of the cDNA and gene for a human D2 dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Waking up to sleep episodes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Pathologic gambling in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Apomorphine: an underutilized therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Parkinson disease gene therapy moves toward the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

The GDNF family: signalling, biological functions and therapeutic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

Neotrofin is transported out of brain by a saturable mechanism: possible involvement of multidrug resistance and monocarboxylic acid transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1335

10.1517/13543784.12.8.1335

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference